BG
MCRB icon

BlackRock Group’s Seres Therapeutics MCRB Stock Holding History

BlackRock Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$117K Buy
585
+63
+12% +$13.7K ﹤0.01% 2803
2016
Q3 		$128K Buy
522
+312
+149% +$109K ﹤0.01% 2767
2016
Q2 		$122K Sell
210
-9,680
-98% -$5.68M ﹤0.01% 2726
2016
Q1 		$5.25M Buy
9,890
+75
+0.8% +$39.1K ﹤0.01% 1068
2015
Q4 		$6.89M Buy
9,815
+175
+2% +$115K ﹤0.01% 1007
2015
Q3 		$5.71M Hold
9,640
– – ﹤0.01% 1064
2015
Q2 		$8M Buy
+9,640
New +$8.41M ﹤0.01% 1020

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock Group's MCRB Position: Q4 2016 in Review

BlackRock Group increased its Seres Therapeutics (MCRB) stake by 12% in Q4 2016, buying an estimated $13.7K and bringing the position to 585 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

BlackRock Group first reported a position in MCRB in Q2 2015 and has held it in 7 quarters since. The position peaked at $8M in Q2 2015. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

  • BlackRock Group held 585 shares of Seres Therapeutics worth $117K as of Q4 2016.
  • BlackRock Group bought 63 Seres Therapeutics shares in Q4 2016, an estimated $13.7K.
  • Seres Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2803 holding.
  • BlackRock Group first reported a position in Seres Therapeutics in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Group's Seres Therapeutics position peaked at $8M in Q2 2015.
  • 89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.